Currently immunosuppressive agents for kidney transplantation can be classified into three categories: induction agents, maintenance therapy, and treatment for rejection. This article is focused on induction therapy. Induction agents can be defined as T-cell depleting, B- and T-cell depleting, and nondepleting T-cell agents. We will focus on the pharmacology, efficacy, major side effects including infection and malignancy, and how to choose an appropriate induction regimen for individualized kidney recipients according to risk and benefit assessment.